Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Andrea PortacciRaffaele CampisiEnrico BuonamicoSanti Nolasco Corrado PelaiaNunzio CrimiAlida BenfanteMassimo TriggianiGiuseppe SpadaroMaria Filomena CaiaffaGiulia SciosciaAikaterini DetorakiGiuseppe ValentiFrancesco PapiaAlessandra TomaselloNicola ScichiloneGirolamo PelaiaClaudia CrimiGiovanna Elisiana Carpagnano

Published in: ERJ open research (2023)

Mepolizumab and benralizumab are safe and effective in patients with EGPA and SEA, since a consistent proportion of patients show a super-response after 12 months of treatment. Further studies will address specific criteria for super-responder assessment in these patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
early onset
air pollution
drug induced